Home>Topics>Stocks>Exact Sciences

Exact Sciences EXAS

  1. All
  2. Commentary
  3. Headlines
    1. A Potential Game Changer In Cancer Screening

      Headlines

      Tue, 16 Sep 2014

      By Ian Cassel : A very important shot was fired last week in the battle for the colorectal cancer diagnostics market. Cancer diagnostics minnow VolitionRx (OTCQB: VNRX ) announced the first tranche of data from its retrospective clinical trial with Hvidovre Hospital in Copenhagen, Denmark. The ...

    2. Exact Sciences continues bull run

      Headlines

      Wed, 3 Sep 2014

      Exact Sciences ( EXAS +7.3% ) is up again in early trading. Shares have more than doubled from the May 8, 2014 low of $10.69. The FDA approved

    3. Mayo Clinic signs on with Cologuard

      Headlines

      Mon, 25 Aug 2014

      The Mayo Clinic will offer Exact Sciences ' ( EXAS +4.8% ) Cologuard as a screen for colorectal cancer. The test will be available to patients through their primary care physicians. It is the first health system to sign on to offer the test. Post your comment!

    4. Update: Exact Sciences' Cologuard Has Been Approved By FDA

      Headlines

      Fri, 15 Aug 2014

      By Andy Batts : Exact Sciences (NASDAQ: EXAS ) has bagged FDA approval for ..... colorectal cancer. Upon approval, Exact Sciences instantly received a proposed ..... healthcare providers for $599. Exact Sciences CEO Kevin Conroy told FierceMedicalDevices

    5. Premarket Gainers / Losers

      Headlines

      Tue, 12 Aug 2014

      Gainers: ICPT +45% . FRF +40% . INSY +15% . SUPN +14% . EXAS +8% . CNAT +8% . ARTX +6% . Losers: DNDN -23% . GALE -12% . CALL -10% . NUAN -9% . TKMR -8% . FLO -8% . HCLP -5% . Post your comment!

    6. BRIEF-MDxHealth says US FDA approves colorectal cancer test using its biomarkers

      Headlines

      Tue, 12 Aug 2014

      * U.S. Food and Drug Administration has approved Exact Sciences ' cologuard stool-DNA-based, non-invasive colorectal cancer screening test

    7. FDA approves Exact Sciences' colorectal screening test

      Headlines

      Mon, 11 Aug 2014

      The FDA clears Exact Sciences ' ( EXAS +2.5% ) Cologuard , a stool-based colorectal screening test ..... proposes to cover the cost of the test once every three years. EXAS shares are up 4% AH on average volume. Post your comment!

    8. From Barron’s, March 31, 2014 (Part 2)

      Commentary

      Sat, 29 Mar 2014

      ancillary-benefit suppliers MET, UNM ; PBMs CVS, ESRX ; managed-care providers AET, UNH, CI ; pg 17]; Exact Sciences [ EXAS ; impending FDA approval of its colon cancer screening test; pg 19]; REITs with DC office exposure [ BDN

    9. Connecting the DOTs: The Role of North America’s ‘Emerging Markets’ in Achieving Energy Independence

      Headlines

      Fri, 18 Oct 2013

      Dakota and Western Canada should grow 10% per year over the next 3 years. In our opinion, North D akota, O klahoma and T exas are critical states from a production, pipeline route, storage and end-market consumption perspective. We believe these

    10. From Barron’s, October 8, 2012 (Part 2)

      Commentary

      Sat, 6 Oct 2012

      favorable trials of muscular dystrophy drug; pg 18); Viacom ( VIA/VIAB ; pg 21); Brink’s ( BCO ; pg 22); Exact Sciences ( EXAS ; DNA-based Cologuard test trials appear promising; pg 25); Walgreen ( WAG ; 5-yr valuation low; pg 34

    « Prev12Next »
    Content Partners